Dengue Fever in the Americas: A Shifting Landscape
Dengue fever remains a significant public health challenge across the Americas. Recent data from the Pan American Health Organization (PAHO) reveals a complex situation, with trends suggesting both progress and ongoing risk. As of epidemiological week 4 of 2026, over 122,090 cases have already been reported, signaling the continued need for vigilance and proactive measures.
2025: A Return to More Typical Levels After Historic Surge
The year 2025 saw a substantial decrease in reported dengue cases compared to the record-breaking numbers of 2024. In 2025, 4,459,521 cases were reported to PAHO’s Health Information Platform for the Americas (PLISA), a 66% drop from the 13,063,434 cases recorded the previous year. However, this decrease doesn’t equate to a lack of concern. Of those cases, 8,966 were classified as severe dengue, resulting in 2,207 deaths – a case fatality rate of 0.05%.
This return to levels more consistent with non-epidemic years is encouraging, but experts caution against complacency. The virus continues to circulate widely and the potential for future outbreaks remains.
The Challenge of Multiple Serotypes
A particularly concerning aspect of the current situation is the circulation of all four dengue virus serotypes (DENV-1, DENV-2, DENV-3, and DENV-4) throughout the region. This poses a greater risk to populations as prior infection with one serotype does not guarantee immunity to others. In fact, subsequent infection with a different serotype can increase the risk of severe dengue.
Several countries are experiencing simultaneous circulation of multiple serotypes. Brazil, Colombia, Costa Rica, El Salvador, Mexico, Panama, and Puerto Rico are all reporting all four serotypes. Argentina, Ecuador, Guatemala, Paraguay, and Peru are currently seeing DENV-1, DENV-2, and DENV-3 co-circulating.
Understanding PLISA and Regional Surveillance
The data driving these insights comes from PLISA, the Health Information Platform for the Americas, operated by PAHO/WHO. PLISA serves as a crucial resource for monitoring and analyzing health trends across the region, enabling informed public health responses. The platform collects data on core health indicators, mortality rates, and disease outbreaks, providing a comprehensive overview of the health landscape.
PAHO’s Regional Dengue Program, established in 2003, works with countries to implement an Integrated Management Strategy (IMS-Dengue) to control and prevent the disease.
Looking Ahead: Potential Future Trends
Several factors could influence the future trajectory of dengue in the Americas. Climate change, with its associated shifts in temperature and rainfall patterns, is expected to expand the geographic range of the mosquito vectors that transmit the virus. Urbanization and population growth also contribute to increased risk, as they create more breeding grounds for mosquitoes.
Continued investment in surveillance, vector control, and vaccine development will be critical to mitigating the impact of dengue. Public awareness campaigns promoting preventative measures, such as eliminating standing water and using mosquito repellent, are also essential.
Frequently Asked Questions (FAQ)
Q: What is PLISA?
A: PLISA is the Pan American Health Organization’s (PAHO) Health Information Platform for the Americas, a data repository used to track health trends and disease outbreaks in the region.
Q: How many dengue serotypes are there?
A: There are four dengue virus serotypes (DENV-1, DENV-2, DENV-3, and DENV-4).
Q: Is dengue fatal?
A: Even as most dengue cases are mild, severe dengue can be fatal. The case fatality rate in 2025 was 0.05%.
Q: What countries are most affected by dengue?
A: Multiple countries across the Americas are affected, with Brazil, Colombia, Costa Rica, El Salvador, Mexico, Panama, and Puerto Rico reporting circulation of all four serotypes.
Did you recognize? Dengue is transmitted by the Aedes aegypti and Aedes albopictus mosquitoes.
Want to learn more about dengue prevention and control? Visit PAHO’s Dengue Data and Analysis page. Share your thoughts and experiences in the comments below!
Worth a look